189,520 Shares in GSK plc (NYSE:GSK) Bought by International Assets Investment Management LLC

International Assets Investment Management LLC bought a new position in shares of GSK plc (NYSE:GSK - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 189,520 shares of the pharmaceutical company's stock, valued at approximately $7,024,000.

Several other large investors also recently made changes to their positions in GSK. Callahan Advisors LLC acquired a new position in shares of GSK during the third quarter valued at $1,119,000. Horizon Bancorp Inc. IN lifted its stake in shares of GSK by 8.9% during the fourth quarter. Horizon Bancorp Inc. IN now owns 3,961 shares of the pharmaceutical company's stock valued at $147,000 after acquiring an additional 323 shares during the period. Avantax Advisory Services Inc. lifted its stake in shares of GSK by 23.6% during the third quarter. Avantax Advisory Services Inc. now owns 76,840 shares of the pharmaceutical company's stock valued at $2,785,000 after acquiring an additional 14,689 shares during the period. Kestra Private Wealth Services LLC lifted its stake in shares of GSK by 18.9% during the third quarter. Kestra Private Wealth Services LLC now owns 25,754 shares of the pharmaceutical company's stock valued at $934,000 after acquiring an additional 4,101 shares during the period. Finally, Envestnet Asset Management Inc. lifted its stake in shares of GSK by 64.7% during the third quarter. Envestnet Asset Management Inc. now owns 1,625,585 shares of the pharmaceutical company's stock valued at $58,927,000 after acquiring an additional 638,544 shares during the period. Institutional investors own 15.74% of the company's stock.

GSK Stock Down 0.4 %

Shares of NYSE GSK traded down $0.16 during mid-day trading on Monday, reaching $40.50. 3,373,652 shares of the company's stock were exchanged, compared to its average volume of 3,538,386. The firm has a market capitalization of $83.93 billion, a price-to-earnings ratio of 13.46, a PEG ratio of 1.86 and a beta of 0.64. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 1.19. The business has a fifty day simple moving average of $42.07 and a 200 day simple moving average of $38.73. GSK plc has a twelve month low of $33.33 and a twelve month high of $43.84.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 EPS for the quarter, missing analysts' consensus estimates of $0.76 by ($0.04). The business had revenue of $10 billion for the quarter, compared to analyst estimates of $9.79 billion. GSK had a return on equity of 51.45% and a net margin of 16.24%. As a group, equities analysts expect that GSK plc will post 4.03 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, April 11th. Investors of record on Friday, February 23rd were issued a dividend of $0.3564 per share. The ex-dividend date of this dividend was Thursday, February 22nd. This is an increase from GSK's previous quarterly dividend of $0.34. This represents a $1.43 dividend on an annualized basis and a dividend yield of 3.52%. GSK's dividend payout ratio (DPR) is presently 52.82%.

Analysts Set New Price Targets

GSK has been the topic of several research reports. Guggenheim raised GSK from a "neutral" rating to a "buy" rating in a research note on Monday, March 4th. Jefferies Financial Group raised GSK from a "hold" rating to a "buy" rating in a research note on Wednesday, January 3rd. Morgan Stanley started coverage on GSK in a research note on Tuesday, January 23rd. They issued an "equal weight" rating on the stock. Finally, Citigroup raised GSK from a "neutral" rating to a "buy" rating in a research note on Tuesday, February 13th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy".

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.